Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT06381232
Recruiting Observational

Collection and Analyses of Physiological, Physical, and Molecular Data From a Diverse Population

NCT06381232 · tracked via the Priya Life Science USA tracker
Sponsor
Viome
Phase
Observational
Started
2018-07-23
Last updated
2024-04-24

Condition(s) studied

General HealthWellness

Investigational drug(s) / intervention(s)

No Intervention

No Intervention: This is an observational study, there are no interventions.

Study summary

The purpose of the study is to collect and analyze physiological, physical, and molecular data from a diverse population to increase our understanding of how such parameters are associated with health and disease.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Anyone that resides in the US at the time of enrollment. Exclusion Criteria: * None

Primary outcome measure(s)

  • Molecular Determinants of Health and Disease — 10 years
    We measure thousands of transcript levels in multiple clinical samples. The primary outcome measures are changes in quantitative gene expression, microbial or human, as a result of transitioning from a healthy state to a disease.

Trial sites (1)

FacilityCityRegionStatus
Viome Life Sciences Bothell Washington Recruiting

More Viome trials in the USA

Metatranscriptomic Markers of Colonic Neoplasia Recruiting
Viome Nutritional Programs to Improve Clinical Outcomes for Metabolic Conditions Recruiting
Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy Recruiting
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System Recruiting
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06381232 on ClinicalTrials.gov ↗ ← All trials in the USA